Evidence map›Paper›PMID 40337837›Full record

ArticleLeukemia & lymphoma2025

Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma.

Carlos A Cruz, Elizabeth R Rodriguez, Maanvi Thawani, Margaret Mazer, Matthew Hayhurst, Madison Swanson, Alexis Romero, J Andrew Livingston, Greg Aune, Debra Eshelman-Kent and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Carlos A CruzDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth R RodriguezDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maanvi ThawaniDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Margaret MazerDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Matthew HayhurstDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Madison SwansonDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alexis RomeroDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0009-0006-2210-6545
J Andrew LivingstonDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Greg AuneUTHealth Science Center San Antonio/Mays Cancer Center, San Antonio, Texas, USA.
Debra Eshelman-KentUTHealth Science Center San Antonio/Mays Cancer Center, San Antonio, Texas, USA.
Branko CuglievanDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael E RothDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sairah AhmedDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Karen AlbrittonCook Children's Hospital, Fort Worth, Texas, USA.
Michelle A T HildebrandtDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-6769-6872

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Role of disparities and aging biomarkers in accelerated cardiac aging among adolescent and young adult cancer survivorsR01CA285599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michelle A T Hildebrandt · 2024 to 2026
$3.2M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA285599
6 · The paper itself

Abstract

Delays in time to treatment (TTT) have been shown to affect cancer survival, yet this has not been investigated in adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients. This retrospective analysis included 508 patients with TTT defined as the time between diagnosis and chemotherapy start. The median TTT for the population was 28 days (IQR: 12-44). Patients who reported fevers and night sweats had shorter TTT than those who did not (

Indexed as

Hodgkin DiseaseTime-to-TreatmentAdolescentAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMalePrognosisRetrospective StudiesYoung Adultadolescent and young adultsHodgkin lymphomatime to treatment

Identifiers

PMID40337837
PMCPMC12353387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.